Chapters

Transcript

Video

Looking forward, when can we expect early data reporting from ARTISTRY-7 and what are we likely to learn about single agent vs. combinatorial approaches based on nemvaleukin? And why was nemvaleukin fast-tracked by the FDA?


Created by

CMEducation Resources | iQ&A Cytokine Immunotherapy Intelligence Zone

Presenter

John L. Hays, MD

John L. Hays, MD

Associate Professor, Department of Internal Medicine
Medical Director of the Clinical Trials Office
The Ohio State University College of Medicine
Wexner Medical Center & James Cancer Hospital
Columbus, OH